Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
27 hedge funds and large institutions have $21.5M invested in Elevation Oncology in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less funds holding
Funds holding: 31 → 27 (-4)
14.52% less ownership
Funds ownership: 80.62% → 66.11% (-15%)
54% less capital invested
Capital invested by funds: $47.2M → $21.5M (-$25.6M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$585K |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$341K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$251K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62K |
| 5 |
VF
Virtu Financial
New York
|
+$54.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.96M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$2.34M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
-$1.86M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.25M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$255K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
26
Driehaus Capital Management
Chicago,
Illinois
| – | -$3.96M | -1,571,509 | Closed |
|
|
VC
27
Vivo Capital
Palo Alto,
California
| – | -$1.25M | -496,844 | Closed |
|
|
B
28
Bailard
Foster City,
California
| – | -$59K | -23,500 | Closed |
|
|
LCM
29
Lynx1 Capital Management
San Juan,
Puerto Rico
| – | -$25K | -10,000 | Closed |
|
30
Morgan Stanley
New York
| – | -$15.6K | -6,224 | -98% |
|
31
Wells Fargo
San Francisco,
California
| – | +$8 | +3 | +8% |
|
ELEV Hedge Fund Activity: Q2 2022 in Review
27 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q2 2022, worth a combined $21.5M — down 54% from $47.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELEV and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $585K. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $3.96M sold.
- 27 institutional investors held Elevation Oncology (ELEV) as of Q2 2022, down from 31 in Q1 2022.
- Funds reported $21.5M of Elevation Oncology stock for Q2 2022, down 54% quarter-over-quarter.
- 2 funds opened new Elevation Oncology positions in Q2 2022 and 6 closed out, a net change of -4 holders.
- The largest Elevation Oncology buyer in Q2 2022 was Renaissance Technologies, an estimated $585K added.
- The largest Elevation Oncology seller in Q2 2022 was Driehaus Capital Management, an estimated $3.96M sold.
Based on aggregated 13F filings for Q2 2022.